On March 10, 2022, Roche Holdings, Inc. successfully completed its issuance of USD 5 billion in aggregate principal amount of senior notes, consisting of USD 1.25 billion 1.882% Notes due 2024, USD 1 billion 2.132% Notes due 2025, USD 1.25 billion 2.314% Notes due 2027, USD 750 million
Tags :Jürg Frick
Roche Kapitalmarkt issued CHF 3 billion Bonds guaranteed by Roche Holding. BNP Paribas (Suisse), Credit Suisse, Deutsche Bank and UBS acted as lead managers. The bonds will be listed on the SIX Swiss Exchange. The transaction
Homburger acted as counsel to Basellandschaftliche Kantonalbank as arranger, agent and lender and Credit Suisse (Switzerland) and Berner Kantonalbank as lenders in connection with the financing of the acquisition of the Bernese gardening company Bä
Homburger acted as counsel to Citi, in its capacity as Coordinator and Bookrunning Mandated Lead Arranger in connection with a Swiss law governed revolving credit facility agreement establishing a CHF 600 million multicurrency revolving credit facility
Homburger advises Roche Holding on the financing of the repurchase of the Novartis stake in Roche Holding On November 3, 2021, Roche Holding, as borrower entered into a CHF 9,814 billion and USD 10 billion bridge facility agreement with
Swiss Prime Site, a listed real estate company, has acquired the Akara Group in Zug, a founder-managed real estate asset manager with around CHF 2.3 bn in assets under management. The acquisition will enable Swiss Prime
Homburger acted as counsel to Citibank Europe plc, UK Branch, in its capacity as Agent, Citibank, N.A., London Branch, in its capacity as Bookrunner or Mandated Lead Arranger and UBS Switzerland, in its capacity
Implenia, a construction and real estate service provider, has successfully completed its issuance of CHF 175 million Bonds on November 26, 2021. The Bonds will be listed on the SIX Swiss Exchange. Homburger acted as counsel to
Sika has signed a definitive agreement to acquire MBCC Group, the former BASF Construction Chemicals, from an affiliate of Lone Star Funds, a global private equity firm, for a consideration of CHF 5.5 billion (EUR 5.2 billion).
Novartis has entered into an agreement to sell 53.3 million (approximately 33%) Roche bearer shares in a bilateral transaction to Roche for a consideration of USD 20.7 billion. Novartis had acquired the stake between 2001 and 2003 for approximately USD 5
